Clinical Research

Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma

Principal Investigator: Mohammed Milhem, MD

Participants in this study have been diagnosed with a type of bone cancer called chondrosarcoma that has spread to other parts of the body or is not able to be removed with surgery. In this study, all subjects will receive the drug pazopanib. This research study is being performed at about 5 clinics across the US. Approximately 47 subjects will take part in this study.

CLEAR III Study

Principal Investigator:Harold P. Adams, Jr., MD

• Purpose: to determine if a study drug called recombinant tissue plasminogen activator (rt-PA), which dissolves blood clots, can help to improve a patient's condition regarding brain blood clots by rapidly removing the clot from the ventricles when compared to placebo (a fluid that does not dissolve blood clots)
• Eligibility: patients ages 18-80 that are admitted with an intraventricular hemorrhage (bleeding in the ventricles or open spaces inside the brain).
• Duration and Involvement: subjects will receive the study medication while they are hospitalized for their hemorrhage. They will be contacted by phone at 3 and 9 months, and follow up in clinic at 30 days, 6 months, and 1 year (final visit) after enrollment into the study.

Investigational Drug Trial for Patients with Multiple Myeloma

Principal Investigator: Mohammed Milhem, MD

Multicenter, Open-Label Single-Arm Study of YONDELIS (trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Excluding Leiomyosarcoma and Liposarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment 

Participants in this research study have been diagnosed with multiple myeloma. This study is being done to see if the investigational drug (tabalumab) is safe and how well it works to help people with this particular cancer. Researchers also want to investigate how much tabalumab should be given and if tabalumab in combinsation with the drugs bortezomib and dexamethasone help people with myeloma. Researchers also want to investigate if the combination of drugs is safe and what side effects are associated with them.

Investigational Vaccine for Melanoma

Principal Investigator:Mohammed Milhem, MD

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence

Participants in this research study have a type of cancer known as melanoma. This study is designed to help determine how safe the investigational vaccine POL-103A is and how it works in humans who have melanoma.

This study will test two different doses of the POL-103A vaccine and one dose of placebo (an injection that will feel like the POL-103A injection but contains no vaccine). This is a blinded study. This means neither the participant or the study doctor will know if the participant is receiving the higher dose of the vaccine, the lower dose of vaccine, or the placebo dose.

Study treatment can last as long as 24 months. With follow up continuing every 3 months.

A Study of ALT-801 in Patients with Relapsed or Refractory Multiple Myeloma

Principal Investigator: Raymond Hohl, MD

Participants in this research study have been diagnosed with a type of multiple myeloma that has grown or spread and cannot be cured by surgery, radiation or any other conventional therapies. The purpose of this research study is to identify the side effects of the study drug, ALT-801, in patients with multiple myeloma, and to find out how safe it is, and how well it is tolerated. Investigators also wish to find out if the study drug can slow the progression of the disease and/or reduce the size of the tumors.